These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11917290)

  • 21. Probability of late rectal morbidity in 125I prostate brachytherapy.
    Waterman FM; Dicker AP
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):342-53. PubMed ID: 12527047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
    Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
    Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.
    Jackson A; Skwarchuk MW; Zelefsky MJ; Cowen DM; Venkatraman ES; Levegrun S; Burman CM; Kutcher GJ; Fuks Z; Liebel SA; Ling CC
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):685-98. PubMed ID: 11172950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
    Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
    Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
    Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy.
    Sanghani MV; Ching J; Schultz D; Cormack R; Loffredo M; McMahon E; Beard C; D'Amico AV
    Urol Oncol; 2004; 22(3):165-8. PubMed ID: 15271308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.
    Michalski JM; Winter K; Purdy JA; Wilder R; Perez CA; Roach M; Parliament M; Pollack A; Markoe A; Harms WB; Sandler H; Cox JD
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):75-80. PubMed ID: 11917289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin.
    Anscher MS; Chang MG; Moghanaki D; Rosu M; Mikkelsen RB; Holdford D; Skinner V; Grob BM; Sanyal A; Wang A; Mukhopadhyay ND
    Am J Clin Oncol; 2018 Jun; 41(6):544-548. PubMed ID: 27438691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.
    Skwarchuk MW; Jackson A; Zelefsky MJ; Venkatraman ES; Cowen DM; Levegrün S; Burman CM; Fuks Z; Leibel SA; Ling CC
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):103-13. PubMed ID: 10758311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma.
    Wachter S; Gerstner N; Goldner G; Pötzi R; Wambersie A; Pötter R
    Radiother Oncol; 2000 Jan; 54(1):11-9. PubMed ID: 10719695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
    Boersma LJ; van den Brink M; Bruce AM; Shouman T; Gras L; te Velde A; Lebesque JV
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):83-92. PubMed ID: 9588921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).
    Cozzarini C; Fiorino C; Ceresoli GL; Cattaneo GM; Bolognesi A; Calandrino R; Villa E
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):688-94. PubMed ID: 12573756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
    Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
    Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.